Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)

Abstract : Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC 50 ) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.
Document type :
Journal articles
Complete list of metadata
Contributor : Patrice Bruscella Connect in order to contact the contributor
Submitted on : Saturday, June 12, 2021 - 10:08:12 AM
Last modification on : Wednesday, March 23, 2022 - 5:20:02 PM

Links full text




Laurent Softic, Rozenn Brillet, François Berry, Nazim Ahnou, Quentin Nevers, et al.. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2020, 64 (7), pp.e00876-20. ⟨10.1128/AAC.00876-20⟩. ⟨inserm-03258933⟩



Record views